PuSH - Publikationsserver des Helmholtz Zentrums München

Zeitschriften-Browsing

64 Datensätze gefunden.
Zum Exportieren der Ergebnisse bitte einloggen.
▮◀ ◀◀ 1 ... 2 ... 3 ... 4 ... ▶▶ ▶▮
Alle Publikationen dieser Seite in den Korb legen
1.
Blüher, M.: Treatment potential of oral small-molecule GLP-1 receptor agonists. Lancet 407, 2478-2480 (2026)
2.
Mora, P.* et al.: Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: A multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet 408, 607-620 (2026)
3.
Mora, P.* et al.: Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: A multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet 408, 621-635 (2026)
4.
Nauck, M.A.* ; Tuttle, K.R.* ; Tschöp, M.H. & Blüher, M.: Glucagon-like receptor agonists and next-generation incretin-based medications: Metabolic, cardiovascular, and renal benefits. Lancet 407, 892-908 (2026)
5.
Mathieu, C.* et al.: Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): A phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial. Lancet 406, 1375-1388 (2025)
6.
Myers, S.S.* et al.: Connecting planetary boundaries and planetary health: A resilient and stable Earth system is crucial for human health. Lancet 406, 315-319 (2025)
7.
Ziegler, A.-G. ; Cengiz, E.* & Kay, T.W.H.*: The future of type 1 diabetes therapy. Lancet 406, 1520-1534 (2025)
8.
Ziegler, A.-G. et al.: Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): A European, randomised, placebo-controlled, primary prevention trial. Lancet 406, 2564-2576 (2025)
9.
GBD 2021 Diseases and Injuries Collaborators (Breitner-Busch, S.): Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: A systematic analysis for the Global Burden of Disease Study 2021. Lancet 403, 2133-2161 (2024)
10.
GBD 2021 Causes of Death Collaborators (Breitner-Busch, S.): Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: A systematic analysis for the Global Burden of Disease Study 2021. Lancet 403, 2100-2132 (2024)
11.
NCD Risk Factor Collaboration (Döring, A.) et al.: Worldwide trends in underweight and obesity from 1990 to 2022: A pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet 403, 1027-1050 (2024)
12.
Melén, E.* et al.: Lung-function trajectories: Relevance and implementation in clinical practice. Lancet 403, 1494-1503 (2024)
13.
Xu, R.* et al.: Global, regional, and national mortality burden attributable to air pollution from landscape fires: A health impact assessment study. Lancet 404, 2447-2459 (2024)
14.
Müller, T.D. & Tschöp, M.H.: Gut-hormone triple agonists: Clinical safety and metabolic benefits. Lancet 400, 1826-1828 (2022)
15.
NCD Risk Factors Collaboration (Döring, A. ; Gieger, C. ; Heier, M. ; Meisinger, C. ; Peters, A. ; Stieber, J. ; Stöckl, D. ; Thorand, B.): Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 398, 957-980 (2021)
16.
Neumann, A.U. ; Goekkaya, M.* ; Dorgham, K.* ; Traidl-Hoffmann, C. & Gorochov, G.*: Tocilizumab in COVID-19 therapy: Who benefits, and how? Lancet 398, 299-300 (2021)
17.
GBD 2019 Diseases (Breitner-Busch, S.): Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet 396, 1204-1222 (2020)
18.
GBD 2019 Risk Factors Collaborators (Breitner-Busch, S.): Global burden of 87 risk factors in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet 396, 1223-1249 (2020)
19.
NCD Risk Factors Collaboration (Meisinger, C. ; Müller-Nurasyid, M. ; Peters, A.): Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: A pooled analysis of 2181 population-based studies with 65 million participants. Lancet 396, 1511-1524 (2020)
20.
von Mutius, E. & Smits, H.H.*: Primary prevention of asthma: From risk and protective factors to targeted strategies for prevention. Lancet 396, 854-866 (2020)
▮◀ ◀◀ 1 ... 2 ... 3 ... 4 ... ▶▶ ▶▮